4 insuﬃciency. Skin biopsy is considered to be a gold standard and should be done to conﬁrm the disease. Conﬂict of Interests The authors declare there is no conﬂict of interests. References [1] J. P. Callen, “Livedoid vasculopathy: what it is and how the patient should be evaluated and treated,” Archives of Dermatology, vol. 142, no. 11, pp. 1481–1482, 2006. [2] J. W. Bard and R. K. Winkelmann, “Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis,” Archives of Dermatology, vol. 96, no. 5, pp. 489–499, 1967. [3] H. R. Gray, J. H. Graham, W. Johnson, and C. F. Burgoon Jr., “Atrophie blanche: periodic painful ulcers of lower extremities. A clinical and histopathological entity,” Archives of Dermatol- ogy, vol. 93, no. 2, pp. 187–193, 1966. [4] B. R. Hairston, M. D. P. Davis, M. R. Pittelkow, and I. Ahmed, “Livedoid vasculopathy: further evidence for procoagulant pathogenesis,” Archives of Dermatology, vol. 142, no. 11, pp. 1413–1418, 2006. [5] J. M. Soria, L. Almasy, J. C. Souto et al., “Linkage analysis demonstrates that the prothrombin G20210A mutation jointly inﬂuences plasma prothrombin levels and risk of thrombosis,” Blood, vol. 95, no. 9, pp. 2780–2785, 2000. [6] S. T. Dunn, R. A. Allen, F. Bates, V. McNamara, and P. Comp, “Abnormal melt curve proﬁle during prothrombin 20210G → A analysis due to the 20209C → T variant,” Blood Coagulation & Fibrinolysis, vol. 17, no. 7, pp. 599–602, 2006. [7] I. Warshawsky, V. Makkar, C. Rimmerman, and K. Kottke- Marchant, “Prothrombin 20209C>T: 16 new cases, association with the 19911A>G polymorphism, and literature review,” Journal of Thrombosis and Haemostasis, vol. 7, no. 9, pp. 1585– 1587, 2009. [8] W. C. Hooper, S. Roberts, N. Dowling, H. Austin, C. Lally, and C. Whitsett, “The prevalence of the prothrombin gene variant C20209T in African-Americans and Caucasians and lack of association with venous thromboembolism,” Thrombosis Research, vol. 118, no. 6, pp. 767–768, 2006. [9] N. von Ahsen and M. Oellerich, “The intronic prothrombin 19911A>G polymorphism inﬂuences splicing eﬃciency and modulates eﬀects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system,” Blood, vol. 103, no. 2, pp. 586–593, 2004. [10] V. Vicente, R. Gonza´lez-Conejero, J. Rivera, and J. Corral, “The prothrombin gene variant 20210A in venous and arterial thromboembolism,” Haematologica, vol. 84, no. 4, pp. 356– 362, 1999. [11] S. Khenifer, L. Thomas, B. Balme, and S. Dalle, “Livedoid vasculopathy: thrombotic or inﬂammatory disease?” Clinical and Experimental Dermatology, vol. 35, no. 7, pp. 693–698, 2010. [12] M. Baccard, M. D. Vignon-Pennamen, M. Janier, M. L. Scrobohaci, and L. Dubertret, “Livedo vasculitis with protein C system deﬁciency,” Archives of Dermatology, vol. 128, no. 10, pp. 1410–1411, 1992. [13] A. Boyvat, N. Kundakc¸i, M. O. A. Babikir, and E. Gu¨rgey, “Livedoid vasculopathy associated with heterozygous protein Case Reports in Medicine C deﬁciency,” British Journal of Dermatology, vol. 143, no. 4, pp. 840–842, 2000. [14] M. Kavala, E. Kocat u¨rk, I. Zindanci, Z. Tu¨rkogˇlu, and S. Altintas¸, “A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin,” Journal of Dermatological Treatment, vol. 19, no. 2, pp. 121–123, 2008. [15] E. Castoldi and J. Rosing, “APC resistance: biological basis and acquired inﬂuences,” Journal of Thrombosis and Haemostasis, vol. 8, no. 3, pp. 445–453, 2010. [16] T. Biedermann, M. J. Flaig, and C. A. Sander, “Livedoid vasculopathy in a patient with factor V mutation (Leiden),” Journal of Cutaneous Pathology, vol. 27, no. 8, pp. 410–412, 2000. [17] C. M. Stein, N. Brown, D. E. Vaughan, C. C. Lang, and A. J. J. Wood, “Regulation of local tissue-type plasminogen acti- vator release by endothelium-dependent and endothelium- independent agonists in human vasculature,” Journal of the American College of Cardiology, vol. 32, no. 1, pp. 117–122, 1998. [18] A. Deng, C. D. Gocke, J. Hess, M. Heyman, M. Paltiel, and A. Gaspari, “Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator,” Archives of Dermatology, vol. 142, no. 11, pp. 1466–1469, 2006. [19] M. Agirbasli, M. Eren, F. Eren et al., “Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy,” Journal of Thrombosis and Thromboly- sis, vol. 32, no. 1, pp. 59–63, 2011. [20] J. Antunes, P. Filipe, M. Andre´, A. Fraga, G. Miltenyi, and M. Marques Gomes, “Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy,” Acta Dermato-Venereologica, vol. 90, no. 1, pp. 91–92, 2010. [21] F. Meiss, W. C. Marsch, and M. Fischer, “Livedoid vascu- lopathy: the role of hyperhomocysteinemia and its simple therapeutic consequences,” European Journal of Dermatology, vol. 16, no. 2, pp. 159–162, 2006. [22] N. A. Irani-Hakime, F. Stephan, R. Kreidy, I. Jureidini, and W. Y. Almawi, “Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity,” Journal of Thrombosis and Thrombolysis, vol. 26, no. 1, pp. 31–34, 2008. [23] P. Frosst, H. J. Blom, R. Milos et al., “A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase,” Nature Genetics, vol. 10, no. 1, pp. 111–113, 1995. [24] N. S. Anavekar and R. Kelly, “Heterozygous prothrombin gene mutation associated with livedoid vasculopathy,” Australasian Journal of Dermatology, vol. 48, no. 2, pp. 120–123, 2007. [25] M. D. P. Davis and W. E. Wysokinski, “Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: response to warfarin,” Journal of the American Academy of Dermatology, vol. 58, no. 3, pp. 512–515, 2008. [26] J. Gotlib, S. Kohler, P. Reicherter, A. E. Oro, and J. L. Zehnder, “Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis,” Archives of Dermatology, vol. 139, no. 8, pp. 1081–1083, 2003. [27] V. Pengo, A. Biasiolo, P. Gresele et al., “Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples,” Journal of Thrombosis and Haemostasis, vol. 5, no. 5, pp. 925–930, 2007.